The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)
Abstract
To learn about the carboxy-terminal extent of amyloid beta-protein (A beta) composition of senile plaques (SPs) in the brain affected with Alzheimer's disease (AD), we employed two end-specific monoclonal antibodies as immunocytochemical probes: one is specific for A beta 40, the carboxyl terminus of A beta 1-40, while the other is specific for A beta 42(43). In the AD cortex, all SPs that were labeled with an authentic antibody were A beta 42(43) positive, while only one-third of which, on the average, were A beta 40 positive. There was a strong correlation between A beta 40 positivity and mature plaques. Two familial AD cortices with the mutation of beta-amyloid protein precursor 717 (beta APP717) (Val to Ile) showed a remarkable predominance of A beta 42(43)-positive, A beta 40-negative plaques. Diffuse plaques, representing the earliest stage of A beta deposition, were exclusively positive for A beta 42(43), but completely negative for A beta 40.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These observations indicate that Aps ending at Ap42(43), which are a minor component of the Ap in human cerebrospinal fluid and plasma, are critically important in AD where they deposit selectively in plaques of all kinds.”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [21]
In the citing paper
“The immunocytochemical results shown here and in a recent report by Iwatsubo et al. (21) demonstrate that BC-05 intensely stains all types of senile plaques, that vessels are stained by both BC-OS and BA-27, and that BA-27 stains plaques poorly, in many cases only faintly staining occasional cored plaques (Fig. 3).”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [21]
In the citing paper
“From studies of trisomy 21 brains (Iwatsubo et al., 1994), it is generally believed that, in human AD, A deposition begins with the formation of diffuse plaques.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“there is good evidence that A1-42 is deposited early and selectively in senile plaques (Iwatsubo et al., 1994).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“In contrast, Aβ40, the major Aβ peptide secreted by cells, appears to be the predominant species deposited in the amyloid deposits in the cerebral vasculature (congophillic angiopathy, CAA) (Gravina et al., 1995; Iwatsubo et al., 1994).”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“These data provide definitive in vivo confirmation of predictions inferred from (1) in vitro studies of Aβ aggregation, (2) effects of PS and certain APP mutations on Aβ production and deposition, and (3) analyses of Aβ peptides in the human AD brain (Gravina et al., 1995; Iwatsubo et al., 1994).”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“Indeed, Aβ42 is the main component of amyloid plaques and is shown to be neurotoxic [30].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [30]
In the citing paper
“the slightly longer Aβ42 species that is specifically linked with FAD is also the first Aβ species deposited in cerebral plaques [82].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [82]
In the citing paper
“The subsequent development of antibodies directed at the free C-terminal ends of Aβ40 or Aβ42 [82] led to the ability to differentiate Aβ from APP labeling”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [82]
Citations
Cites
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Cited by
Sorted by citations
Items 201–300 of 1,000
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Yamada, K., & Nabeshima, T. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00081-4 · Cited by 192
The γ-Secretase Complex: Membrane-Embedded Proteolytic Ensemble
Wolfe, M. S. (2006) · Biochemistry · doi:10.1021/bi060799c · Cited by 161
Theuns, J., Brouwers, N., Engelborghs, S., Sleegers, K., Bogaerts, V., Corsmit, E., Pooter, T. D., van Duijn, C. M., Deyn, P. P. D., & Broeckhoven, C. V. (2006) · The American Journal of Human Genetics · doi:10.1086/504044 · Cited by 188
Zou, K., Yamaguchi, H., Akatsu, H., Sakamoto, T., Ko, M.-H., Mizoguchi, K., Gong, J.-S., Yu, W., Yamamoto, T., Kosaka, K., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1549-07.2007 · Cited by 193
Mitani, Y., Yarimizu, J., Saita, K., Uchino, H., Akashiba, H., Shitaka, Y., Ni, K., & Matsuoka, N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4264-11.2012 · Cited by 203
Biology of Aβ Amyloid in Alzheimer's Disease
Wisniewski, T., Ghiso, J., & Frangione, B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0147 · Cited by 134
Marcinkiewicz, M. M., & Seidah, N. G. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752133.x · Cited by 190
Mann, D. M. A., Iwatsubo, T., Ihara, Y., Cairns, N. J., Lantos, P. L., Bogdanović, N., Lannfelt, L., Winblad, B. G., Maat–Schieman, M. L. C., & Rossor, M. N. (1996) · Europe PMC (PubMed Central) · Cited by 184
Self-citationCalcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
Cascella, R., & Cecchi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094914 · Cited by 194
Mann, D. M. A., Iwatsubo, T., Cairns, N. J., Lantos, P. L., Nochlin, D., Sumi, S. M., Bird, T. D., Poorkaj, P., Hardy, J., Hutton, M., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400205 · Cited by 184
Self-citationMetal ions as modulators of protein conformation and misfolding in neurodegeneration
Leal, S. S., Botelho, H. M., & Gomes, C. M. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.04.004 · Cited by 187
Mann, D. M. A., Pickering-Brown, S. M., Takeuchi, A., & Iwatsubo, T. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64688-3 · Cited by 182
Self-citationAlzheimer’s Disease: The Link Between Amyloid-β and Neurovascular Dysfunction
Solis, E., Hascup, K. N., & Hascup, E. R. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200473 · Cited by 192
Güntert, A., Döbeli, H., & Bohrmann, B. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.027 · Cited by 180
BACE1 activity is modulated by cell-associated sphingosine-1-phosphate
Takasugi, N., Sasaki, T., Suzuki, K., Osawa, S., Isshiki, H., Hori, Y., Shimada, N., Higo, T., Yokoshima, S., Fukuyama, T., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6467-10.2011 · Cited by 181
Self-citationA β 42 and A β 40: similarities and differences
Qiu, T., Liu, Q., Chen, Y., Zhao, Y., & Li, Y. (2015) · Journal of Peptide Science · doi:10.1002/psc.2789 · Cited by 180
Transgenic mouse models of Alzheimer's disease
Janus, C., & Westaway, D. A. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00524-8 · Cited by 181
Analysis of the Secondary Structure of β-Amyloid (Aβ42) Fibrils by Systematic Proline Replacement
Morimoto, A., Irie, K., Murakami, K., Masuda, Y., Ohigashi, H., Nagao, M., Fukuda, H., Shimizu, T., & Shirasawa, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406262200 · Cited by 177
Qiu, W. Q., Ye, Z., Kholodenko, D., Seubert, P. A., & Selkoe, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.10.6641 · Cited by 182
The grey mouse lemur: A non-human primate model for ageing studies
Languille, S., Blanc, S., Blin, O. J., Canale, C. I., Dal‐Pan, A., Devau, G., Dhénain, M., Dorieux, O., Epelbaum, J., Gomez, D., et al. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.07.001 · Cited by 175
Palmitoylation of amyloid precursor protein regulates amyloidogenic processing in lipid rafts
Bhattacharyya, R., Barren, C., & Kovacs, D. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4704-12.2013 · Cited by 171
Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways.
Khan, S. M., Cassarino, D. S., Abramova, N. N., Keeney, P. M., Borland, M. K., Pa, T., Krebs, C. T., Bennett, J. C., Parks, J. K., Swerdlow, R. H., et al. (2000) · PubMed · Cited by 176
Bouter, Y., Dietrich, K., Wittnam, J. L., Rezaei-Ghaleh, N., Pillot, T., Papot-Couturier, S., Lefebvre, T., Sprenger, F., Wirths, O., Zweckstetter, M., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1129-2 · Cited by 175
Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
Gasparini, L., Racchi, M., Binetti, G. G., Trabucchi, M., Solerte, S. B., Alkon, D. L., Etcheberrigaray, R., Gibson, G. E., Blass, J. P., Paoletti, R., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.1.17 · Cited by 177
Stable Association of Presenilin Derivatives and Absence of Presenilin Interactions with APP
Thinakaran, G., Regard, J. B., Bouton, C. M. L. S., Harris, C. L., Price, D. L., Borchelt, D., & Sisodia, S. S. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0171 · Cited by 173
PET amyloid-beta imaging in preclinical Alzheimer's disease
Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 188
Development and Mechanism of γ-Secretase Modulators for Alzheimer’s Disease
Crump, C. J., Johnson, D. S., & Li, Y. (2013) · Biochemistry · doi:10.1021/bi400377p · Cited by 174
5‐Lipoxygenase gene disruption reduces amyloid‐β pathology in a mouse model of Alzheimer's disease
Firuzi, O., Zhuo, J., Chinnici, C. M., Wısnıewskı, T., & Praricò, D. (2007) · The FASEB Journal · doi:10.1096/fj.07-9131.com · Cited by 169
Matsuzaki, K. (2014) · Accounts of Chemical Research · doi:10.1021/ar500127z · Cited by 173
Evidence for a physical interaction between presenilin and Notch
Ray, W. J., Yao, M., Nowotny, P., Mumm, J. S., Zhang, W., Wu, J. Y., Kopan, R., & Goate, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3263 · Cited by 167
Boespflug, E. L., & Iliff, J. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.031 · Cited by 179
Verdile, G. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.028 · Cited by 181
Qian, S., Jiang, P., Guan, X.-M., Singh, G., Trumbauer, M. E., Yu, H. H., Chen, H. Y., der Ploeg, L. H. T. V., & Zheng, H. (1998) · Neuron · doi:10.1016/s0896-6273(00)80999-x · Cited by 172
Dickson, D. W. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00065-1 · Cited by 168
The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide
Storey, & Cappai, R. (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00164.x · Cited by 172
Matlack, K. E. S., Tardiff, D. F., Narayan, P. S., Hamamichi, S., Caldwell, K. A., Caldwell, G. A., & Lindquist, S. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402228111 · Cited by 166
Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid
Teunissen, C. E., de Vente, J., Steinbusch, H. W. M., & Bruijn, C. D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00328-1 · Cited by 169
The $gamma;-secretase complex: machinery for intramembrane proteolysis
Iwatsubo, T. (2004) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2004.05.010 · Cited by 177
Self-citationSubcellular Topography of Neuronal Aβ Peptide in APPxPS1 Transgenic Mice
Langui, D., Girardot, N., El Hachimi, K. H., Allinquant, B., Blanchard, V., Pradier, L., & Duyckaerts, C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63405-0 · Cited by 165
Iwatsubo, T., Yamaguchi, H., Fujimuro, M., Yokosawa, H., Ihara, Y., Trojanowski, J. Q., & Lee, V. M. (1996) · Europe PMC (PubMed Central) · Cited by 165
Self-citationMorohashi, Y., Hatano, N., Ohya, S., Takikawa, R., Watabiki, T., Takasugi, N., Imaizumi, Y., Tomita, T., & Iwatsubo, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200897200 · Cited by 164
Self-citationMoechars, D., Lorent, K., De Strooper, B., Dewachter, I., & Van Leuven, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00468.x · Cited by 201
Sato, N., & Morishita, R. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00199 · Cited by 167
LaFerla, F. M., Troncoso, J. C., Strickland, D. K., Kawas, C. H., & Jay, G. D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119536 · Cited by 165
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study
López, O. L., Kuller, L. H., Mehta, P. D., Becker, J. T., Gach, H. M., Sweet, R. A., Chang, Y., Tracy, R. P., & DeKosky, S. T. (2008) · Neurology · doi:10.1212/01.wnl.0000306696.82017.66 · Cited by 158
Murakami, K., Irie, K., Ohigashi, H., Hara, H., Nagao, M., Shimizu, T., & Shirasawa, T. (2005) · Journal of the American Chemical Society · doi:10.1021/ja054041c · Cited by 161
Duan, L., Bhattacharyya, B. J., Belmadani, A. A., Pan, L., Miller, R. J., & Kessler, J. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-3 · Cited by 165
Grimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Zimmer, V. C., & Hartmann, T. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00098 · Cited by 170
Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus
Zhang, C.-E., Tian, Q., Wei, W., Peng, J.-H., Liu, G., Zhou, X., Wang, Q., Wang, D. W., & Wang, J. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.015 · Cited by 159
Klafki, H., Abramowski, D., Swoboda, R., Paganetti, P., & Staufenbiel, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28655 · Cited by 159
Kumar-Singh, S. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2589 · Cited by 158
Relationship between β-amyloid degradation and the 26S proteasome in neural cells
Salon, M. L., Pasquini, L. A., Moreno, M. B., Pasquini, J. M., & Soto, E. F. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(02)00060-2 · Cited by 161
Differences in β-strand Populations of Monomeric Aβ40 and Aβ42
Ball, K. A., Phillips, A. H., Wemmer, D. E., & Head-Gordon, T. L. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2013.04.056 · Cited by 157
Murphy, M. P., Hickman, L., Eckman, C. B., Uljon, S., Wang, R., & Golde, T. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11914 · Cited by 156
Genetics of Alzheimer's Disease
Guerreiro, R. J., & Hardy, J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0295-9 · Cited by 168
Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms
Czech, C., Tremp, G. L., & Pradier, L. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00033-7 · Cited by 160
Accumulation and Aggregation of Amyloid β-Protein in Late Endosomes of Niemann-Pick Type C Cells
Yamazaki, T., Chang, T., Haass, C., & Ihara, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009598200 · Cited by 156
Self-citationZou, K., Kim, D. S., Kakio, A., Byun, K., Gong, J., Kim, J. W., Kim, M. J., Sawamura, N., Nishimoto, S., Matsuzaki, K., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02018.x · Cited by 160
Jeong, J. S., Ansaloni, A., Mezzenga, R., Lashuel, H. A., & Dietler, G. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.02.005 · Cited by 152
Fabiani, C., & Antollini, S. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00309 · Cited by 158
Amyloid β protein in plasma from patients with sporadic Alzheimer's disease
Tamaoka, A., Fukushima, T., Sawamura, N., Ishikawa, K., Oguni, E., Komatsuzaki, Y., & Shoji, S. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00143-8 · Cited by 154
Vascular and parenchymal Aβ deposition in the aging dog: correlation with behavior
Colle, M.-A. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00113-5 · Cited by 154
The Genetics of the Amyloidoses
Buxbaum, J. N., & Tagoe, C. E. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.543 · Cited by 153
Ward, R. V., JENNINGS, K. H., Jepras, R., Neville, W. A., OWEN, D. E., HAWKINS, J., Christie, G., Davis, J. B., George, A. R., Karran, E. H., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480137 · Cited by 153
Partial Purification and Characterization of γ-Secretase from Post-mortem Human Brain
Farmery, M. R., Tjernberg, L. O., Pursglove, S. E., Bergman, A., Winblad, B. G., & Näslund, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211992200 · Cited by 152
Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?
Jellinger, K. A., & Attems, J. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0088-2 · Cited by 157
Beach, T. G., Kuo, Y., Spiegel, K., Emmerling, M. R., Sue, L. I., Kokjohn, K., & Roher, A. E. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.4.308 · Cited by 157
Regitz, C., Fitzenberger, E., Mahn, F. L., Dußling, L. M., & Wenzel, U. (2015) · European Journal of Nutrition · doi:10.1007/s00394-015-0894-1 · Cited by 152
Vitamin A and Alzheimer's disease
Ono, K., & Yamada, M. (2011) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00786.x · Cited by 156
Nagai, A., Nakagawa, E., Hatori, K., Choi, H. B., McLarnon, J. G., Lee, M. A., & Kim, S. U. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0437 · Cited by 156
Portelius, E., Tran, A. J., Andréasson, U., Persson, R., Brinkmalm, G., Zetterberg, H., Blennow, K., & Brinkmalm, A. (2007) · Journal of Proteome Research · doi:10.1021/pr0703627 · Cited by 149
CSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151
Alzheimer amyloid abeta1-42 channels: effects of solvent, pH, and Congo Red.
Hirakura, Y., Lin, M., & Kagan, B. L. (1999) · PubMed · Cited by 151
Genetic and host factors for dementia in Down's syndrome
Schupf, N. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.405 · Cited by 188
Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome
Schupf, N., Patel, B. N., Silverman, W. P., Zigman, W. B., Zhong, N., Tycko, B., Mehta, P. D., & Mayeux, R. P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01657-3 · Cited by 148
Nontoxic Amyloid β Peptide1-42 Suppresses Acetylcholine Synthesis
Hoshi, M. M., Takashima, A., Murayama, M., Yasutake, K., Yoshida, N., Ishiguro, K., Hoshino, T., & Imahori, K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2038 · Cited by 151
Landman, N., Jeong, S. Y., Shin, S. Y., Voronov, S. V., Serban, G., Kang, M. S., Park, M. K., Di Paolo, G., Chung, S., & Kim, T.-W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604954103 · Cited by 149
Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells.
Asami-Odaka, A., Ishibashi, Y., Kikuchi, T., Kitada, C., & Suzuki, N. (1995) · Biochemistry · doi:10.1021/bi00032a022 · Cited by 153
Self-citationAβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains
Welander, H., Frånberg, J., Graff, C., Sundström, E., Winblad, B. G., & Tjernberg, L. O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06170.x · Cited by 150
Jonghe, C. D., Zehr, C., Yager, D., Prada, C.-M., Younkin, S. G., Hendriks, L., Broeckhoven, C. V., & Eckman, C. B. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0202 · Cited by 151
Secretase inhibitors and modulators for Alzheimer’s disease treatment
Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 148
THE GENETICS AND MOLECULAR PATHOLOGY OF ALZHEIMER'S DISEASE
Selkoe, D. J. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70232-2 · Cited by 146
(1998) · Europe PMC (PubMed Central) · Cited by 146
Self-citationHyperaccumulation of FAD-linked presenilin 1 variants in vivo
Lee, M. K., Borchelt, D., Kim, G. J., Thinakaran, G., Slunt, H. H., Ratovitski, T., Martin, L. J., Kittur, A., Gandy, S., Levey, A. I., et al. (1997) · Nature Medicine · doi:10.1038/nm0797-756 · Cited by 148
Morishima‐Kawashima, M., & Ihara, Y. (1998) · Biochemistry · doi:10.1021/bi981843u · Cited by 146
Self-citationQuantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease.
(1998) · Europe PMC (PubMed Central) · Cited by 145
Self-citationAlzheimer’s Disease as Proteolytic Disorders: Anabolism and Catabolism of β-Amyloid
Saido, T. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00033-5 · Cited by 140
Murakami, K., Irie, K., Morimoto, A., Ohigashi, H., Shindo, M., Nagao, M., Shimizu, T., & Shirasawa, T. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00430-8 · Cited by 146
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 144
Sato, T., Dohmae, N., Qi, Y. A., Kakuda, N., Misonou, H., Mitsumori, R., Maruyama, H., Koo, E. H., Haass, C., Takio, K., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211161200 · Cited by 150
Self-citationLewis, H. D., Beher, D., Cookson, N., Oakley, A. E., Piggott, M. A., Morris, C. M., Jaros, E., Perry, R., Ince, P. G., Kenny, R. A., et al. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00696.x · Cited by 143
Inhibition and Modulation of γ-Secretase for Alzheimer's Disease
Wolfe, M. S. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.010 · Cited by 146
β-Amyloid Mediated Nitration of Manganese Superoxide Dismutase
Muthuswamy, A., Tangpong, J., Keller, J. N., Murphy, M. P., Markesbery, W. R., Kiningham, K. K., & Clair, D. K. S. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051223 · Cited by 144
Smith, D. H., Nakamura, M., McIntosh, T. K., Wang, J., Rodríguez, A., Chen, X.-H., Raghupathi, R., Saatman, K. E., Clemens, J., Schmidt, M. L., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65643-x · Cited by 143
Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?
Bayer, T. A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.007 · Cited by 149
González-Marrero, I., Giménez‐Llort, L., Johanson, C. E., Carmona-Calero, E. M., Castañeyra-Ruiz, L., Armas, J. M. B., Castañeyra-Perdomo, A., & Castro-Fuentes, R. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00017 · Cited by 146
Regitz, C., Dußling, L. M., & Wenzel, U. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400014 · Cited by 142
Diffuse Plaques Contain C-terminal Aβ42and not Aβ40: Evidence From Cats and Dogs
Cummings, B. J., Satou, T., Head, E., Milgram, N. W., Cole, G. M., Savage, M. J., Podlisny, M. B., Selkoe, D. J., Siman, R. G., Greenberg, B., et al. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00062-0 · Cited by 140
α-Helix targeting reduces amyloid-β peptide toxicity
Nerelius, C., Sandegren, A., Sargsyan, H., Raunak, R., Leijonmarck, H., Chatterjee, U., Fisahn, A., Imarisio, S., Lomas, D. A., Crowther, D. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810364106 · Cited by 141
Metadata
- Authors
- Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y.
- Affiliations
- Takeda (Japan) (JP)
- The University of Tokyo (JP)
- University of Tsukuba (JP)
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 1994-07
- Volume
- 13
- Issue
- 1
- Pages
- 45-53
- ISSN
- 0896-6273 (ISSN-L)
- OpenAlex
- W1991435932
- Cited by
- 1,774
- References
- 41
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 53 · 2023: 49 · 2022: 49 · 2021: 55 · 2020: 68 · 2019: 49 · 2018: 41 · 2017: 49 · 2016: 52 · 2015: 45 · 2014: 68 · 2013: 69 · 2012: 66
- FWCI
- 35.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Aβ40, amyloid plaques, Alzheimer's disease, familial Alzheimer's disease, plaque maturation, diffuse plaques, immunocytochemistry
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Antibodies, Monoclonal, Brain, Cerebral Cortex, Female, Humans, Immunoenzyme Techniques, Male, Middle Aged, Mutation, Peptide Fragments, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
